European Commission Approves Betta’s Ensartinib as Gevalka – Next‑Generation ALK Inhibitor for Advanced NSCLC Marks Chinese Innovation’s Entry Into the EU Market

Betta Pharmaceuticals (SHE: 300558) announced that the Marketing Authorization Application (MAA) for ensartinib – submitted by Xcovery, its majority‑owned subsidiary – received approval from the European Commission. Indicated for the…

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.